The earnings call reflects a strong overall performance by Alvotech, with significant revenue growth, positive cash flow, and strategic market expansion. However, the lumpiness in licensing revenues and anticipated challenges in the U.S. market pose some concerns.

Company Guidance

During the Alvotech Second Quarter 2025 Earnings Conference Call, the company provided detailed guidance on its financial performance and future expectations. The first half of 2025 showcased strong growth, with revenues increasing by 30% year-on-year to $306 million, driven by a 200% rise in product revenues, particularly from biosimilars to Humira and STELARA. Adjusted EBITDA reached $54 million, maintaining positive momentum for the fifth consecutive quarter. Despite expectations of a softer third quarter, the company anticipates a strong fourth quarter, bolstered by new product launches and milestone achievements. Alvotech also reported significant cash flow improvements, with $77 million generated from operations, and successfully reduced its capital costs by renegotiating its debt terms. The company's strategic focus remains on expanding its product reach, enhancing R&D efforts, and maintaining operational efficiency to support sustainable long-term growth.

Revenue Growth and Product Performance

Alvotech achieved a 30% year-on-year revenue growth in the first half of 2025, totaling $306 million, with strong product revenues of $205 million driven by increased sales of biosimilars to Humira and STELARA.

Positive Cash Flow and Operational Efficiency

The company generated $77 million of positive cash flow from operations in the first half, a net improvement of $161 million year-on-year, marking the strongest quarter for operating cash flow in Alvotech's history.

Biosimilar Market Expansion

Alvotech's biosimilar to Humira, SIMLANDI, achieved over 40% share of the U.S. Humira market, and its biosimilar to STELARA, SELARSDI, captured over 20% of the U.S. market with continued strong performance in Europe.

Strategic Partnerships and Acquisitions

Alvotech expanded partnerships with Advanz Pharma and Dr. Reddy's, licensed rights to multiple biosimilar candidates, and completed the acquisition of Ivers-Lee in Switzerland and the R&D operation of Xbrane in Sweden.

Alvotech (ALVO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ALVO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	-0.02 / -	-0.03	―	―	―
Aug 13, 2025	2025 (Q2)	-0.05 / 0.03	0.14	-78.57% (-0.11)
May 07, 2025	2025 (Q1)	-0.11 / 0.35	-0.89	139.33% (+1.24)
Mar 26, 2025	2025 (Q4)	>-0.01 / -	-0.8	―
Nov 13, 2024	2024 (Q3)	-0.06 / -0.03	-0.58	94.83% (+0.55)
Aug 15, 2024	2024 (Q2)	<0.01 / 0.14	-0.06	333.33% (+0.20)
May 21, 2024	2024 (Q1)	-0.08 / -0.89	-1.24	28.23% (+0.35)
Mar 26, 2024	2024 (Q4)	- / -	-1.289	―	―	―
Mar 20, 2024	2023 (Q4)	0.04 / -0.80	-1.289	37.94% (+0.49)
Nov 28, 2023	2023 (Q3)	-0.07 / -0.58	0.02	-3000.00% (-0.60)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ALVO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$8.96	$8.48	-5.36%
May 07, 2025	$7.94	$9.38	+18.14%
Mar 26, 2025	$11.55	$10.36	-10.30%
Nov 13, 2024	$11.93	$12.07	+1.17%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Alvotech (ALVO) report earnings?

Alvotech (ALVO) is schdueled to report earning on Nov 12, 2025, After Close (Confirmed).

What is Alvotech (ALVO) earnings time?

Alvotech (ALVO) earnings time is at Nov 12, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ALVO EPS forecast?

ALVO EPS forecast for the fiscal quarter 2025 (Q3) is -0.02.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing